Characterization of a Population Living in Highly Contaminated Settlement in Campania Region (SPES)

July 27, 2023 updated by: Francesca De Filippis
some areas in the Campania region (southern Italy) have attracted media coverage in the past 15 years, and are considered a dramatic example of an extremely polluted area. The environmental pollution issue has become a significant concern in the Campania Region as a result of the "waste management crisis" that mainly affects the northern part of the region, encompassing 91 municipalities. As a consequence, in the last few decades, a large rural area between the provinces of Naples and Caserta, primarily used for agriculture and livestock breeding, was considered to be at high risk of contamination due to the illegal disposal of urban and industrial waste. In these landfills, a broad range of hazardous wastes from different parts of Italy has been found. In addition, the wastes have often been open-air burned, leading to this area being named the "Land of Fires". Senior and Mazza first highlighted the high incidence of cancer deaths in a specific area of the Campania region (compared to regional and national rates), which was identified by the authors as the "triangle of death". Afterwards, several studies reported a link between illegal waste disposal and an increased risk of cancer for the population, potentially associated with human exposure to carcinogenic substances such as dioxins, dioxin-like compounds, or polycyclic aromatic hydrocarbons, which can be released into air, soil, and water bodies through the illegal dumping and burning of waste. Within this study, 4,227 subjects were enrolled in the SPES trial, considering healthy subjects living in several regional areas with different environmental pressures. Blood dioxins and heavy metals were analyzed. Gut microbiome was analyzed on a subset of 359 subjects from the three different exposure area.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This study involved a screening of healthy adults from Campania region recruited in the human biomonitoring study SPES (http://spes.campaniatrasparente.it), promoted by the Istituto Zooprofilattico Sperimentale del Mezzogiorno (IZSM) of Portici (Italy) in collaboration with the National Tumor Institute IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico) "G. Pascale" in Naples. Considering different source of environmental pressure (e.g., land use and population density, presence of contaminated sites, quality of air, soil and water bodies, closeness to waste management plants and illegal waste spills and fires), Pizzolante and colleagues developed an integrated model to compute the Municipality Index of Environmental Pressure (MIEP). The MIEP takes into account all factors involved in the pollution processes, including the sources of contaminants and their migration pathways. The MIEP enables the identification of 21 homogeneous sub-clusters, which include several municipalities based on their environmental pressure scores. This categorization has resulted in three macro-areas with increasing levels of impact pressure: LOW, MEDIUM and HIGH, as described by Pierri and colleagues. In 2016, a total of 4,227 subjects were enrolled in the SPES trial, considering healthy subjects living in several regional areas with different environmental pressures. A subgroup of 359 subjects residing in the three impact areas was randomly selected from the entire SPES cohort for gut microbiome analysis, in order to define the impact of environmental pollution on gut microbial communities.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
4227

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Healthy adults (20-50 years/old) resident in one of the municipalities under study for at least 5 years (Campania Region, Italy) grouped according to the environmental impact (high, medium and low) (as reported in http://www.campaniatrasparente.it)

Description

Inclusion criteria:

  • healthy subjects (no severe, chronic or neoplastic conditions)
  • 20-50 years old
  • both sexes
  • no important viral infection (HIV, HCV, HBV)
  • no use of drugs
  • no alcohol abuse
  • no obesity of II, III and IV classes.
  • resident in one of the municipalities under study for at least 5 years (Campania Region, Italy)

Exclusion criteria:

  • age < 20 and > 50 years at enrollment
  • severe, chronic or neoplastic conditions
  • viral infections (HIV, HCV, HBV)
  • use of drugs or alcohol
  • obesity

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
High environmental pollution group (HIGH)
subjects living in area characterized by high environmental pollution, as defined by Pizzolante et al. [Development of a municipality index of environmental pressure in Campania, Italy. Future Sci. OA 7(7), FSO720 (2021).]
Other: Determination of dioxins (PCDD/Fs), polychlorinated biphenyls (PCBs) and trace elements
Peripheral blood (about 100 mL in several aliquots) was collected from the volunteers, in the early morning, in blood collection tubes (SST II Advance Tubes, BD Vacutainer). The samples were left for approximately 50 min, then the serum was separated from whole blood by centrifugation at 2,000 rcf for 10 min at 4 °C and then aliquots were stored at -80°C until analysis.
Medium environmental pollution group (MEDIUM)
subjects living in area characterized by medium environmental pollution, as defined by Pizzolante et al. [Development of a municipality index of environmental pressure in Campania, Italy. Future Sci. OA 7(7), FSO720 (2021).]
Other: Determination of dioxins (PCDD/Fs), polychlorinated biphenyls (PCBs) and trace elements
Peripheral blood (about 100 mL in several aliquots) was collected from the volunteers, in the early morning, in blood collection tubes (SST II Advance Tubes, BD Vacutainer). The samples were left for approximately 50 min, then the serum was separated from whole blood by centrifugation at 2,000 rcf for 10 min at 4 °C and then aliquots were stored at -80°C until analysis.
Low environmental pollution group (LOW)
subjects living in area characterized by low environmental pollution, as defined by Pizzolante et al. [Development of a municipality index of environmental pressure in Campania, Italy. Future Sci. OA 7(7), FSO720 (2021).]
Other: Determination of dioxins (PCDD/Fs), polychlorinated biphenyls (PCBs) and trace elements
Peripheral blood (about 100 mL in several aliquots) was collected from the volunteers, in the early morning, in blood collection tubes (SST II Advance Tubes, BD Vacutainer). The samples were left for approximately 50 min, then the serum was separated from whole blood by centrifugation at 2,000 rcf for 10 min at 4 °C and then aliquots were stored at -80°C until analysis.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Comparison of plasmatic concentration of dioxins (PCDD/Fs) and polychlorinated biphenyls (PCBs) in subjects from high, medium and low pollution area as assessed by HRGC-HRMS
Time Frame: at enrollement
measure of PCDD/Fs and PCBs in human blood serum using High-Resolution Gas Chromathography coupled to High-Resolution Mass Spectrometry (HRGC-HRMS) analysis
at enrollement
Comparison of plasmatic concentration of trace elements in subjects from high, medium and low pollution area as assessed by ICP-MS
Time Frame: at enrollement
trace elements (arsenic, beryllium, cadmium, cobalt, chromium, copper, iron, mercury, lithium, manganese, molybdenum, nickel, lead, antimony, selenium, strontium, thallium, vanadium, and zinc) were determined in human plasma using an inductively coupled plasma mass spectrometer (ICP-MS)
at enrollement
Comparison of gut microbiome composition and functions in subjects from high, medium and low pollution area as assessed by metagenomics
Time Frame: at enrollement
Microbiome composition and potential functions was determined by shotgun metagenomics (Illumina paired-end sequencing, 2x150bp). The massive amount of sequences obtained was analyzed by using state of the art bioinformatics tools and the presence and relative abundance of the microbial species and genes occurring in each sample was determined.
at enrollement

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Francesca De Filippis

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
September 10, 2016

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
August 3, 2017

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
August 3, 2017

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
July 20, 2023

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 27, 2023

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
August 4, 2023

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
August 4, 2023

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 27, 2023

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 59

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings